[Pharmacological treatment of motor symptoms in Parkinson's diseases]. / Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson.
Nervenarzt
; 88(4): 373-382, 2017 Apr.
Article
em De
| MEDLINE
| ID: mdl-28289795
Since the 1960s many substance classes have been introduced for treatment of idiopathic Parkinson's disease. The most important and effective medication is levodopa (L-dopa) always in combination with a decarboxylase inhibitor. In addition, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, Nmethyl-D-aspartate (NMDA) antagonists and very rarely anticholinergics are administered depending on the motor symptoms, age and a multitude of other factors. Fortunately, within the substance classes there are various preparations, which also have different effects. In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication. In addition important aspects are interactions and reciprocal actions. In the foreseeable future, different substance classes are to be expected.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Antagonistas de Dopamina
/
Inibidores da Monoaminoxidase
/
Transtornos dos Movimentos
/
Antiparkinsonianos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
Limite:
Humans
Idioma:
De
Revista:
Nervenarzt
Ano de publicação:
2017
Tipo de documento:
Article
País de publicação:
Alemanha